Bootylicious fly named after Beyonce
13 January, 2012 by Tim DeanA new species of horse fly with a notably resplendent abdomen has been named after the American pop diva, Beyonce.
A new year, a new look and good news is rolling in already…
12 January, 2012 by AusBiotech2011 ended on a high for the Australian biotechnology industry, and 2012 is already off to a strong start for the sector.
Australian native plants found to have anti-microbial properties
12 January, 2012 by Staff WritersA Queensland collaborative research programme has found common native Australian plums can extend the shelf life of meat products.
Starpharma to advance with phase III studies for VivaGel
11 January, 2012 by Tim DeanPhase III trials of VivaGel to commence shortly after receiving FDA agreement on study design in anticipation of application for regulatory approval.
Bionomics scores deal worth up to US$345 million
11 January, 2012 by Tim DeanDeal with US pharmaceutical company Ironwood to develop anti-anxiety compound BNC210 could be worth up to US$345 million for the Adelaide-based biotech.
Feature: Fever pitch
23 December, 2011 by Fiona WylieProfessor Suresh Mahalingam and his team have made some intriguing discoveries that could lead to treatments of some nasty mosquito-borne diseases.
QRxPharma to form US sales partnership
21 December, 2011 by Dylan Bushell-EmblingDrug development company QRxPharma (ASX:QRX) has agreed to form a partnership with Actavis covering commercialisation of its lead product, MoxDuo, in the US market.
Viralytics raises $4.7m to fund melanoma trial
20 December, 2011 by Staff WritersCash levels boosted to over $8 million to help fund phase II melanoma trial.
Trial success sees Clinuvel near European filing for Scenesse
20 December, 2011 by Tim DeanClinuvel’s photoprotective drug Scenesse has shown it has a significant benefit for sufferers of erythropoietic protoporphyria, bringing the company closer to filing in Europe for marketing authorisation.
A look at year that was and what’s in store for 2012
19 December, 2011 by AusBiotechIn the year that AusBiotech celebrated 25 years since it began as the Australian Biotechnology Association, 2011 has been the most action-packed for many years. Dr Anna Lavelle, CEO of AusBiotech, takes a look at the year that was and what 2012 might hold for the biotechnology sector.
HealthLinx prepares to wrap up OvPlex trial
16 December, 2011 by Dylan Bushell-EmblingDiagnostics product developer HealthLinx (ASX:HTX) will finalise recruitment for a large trial of its OvPlex ovarian cancer biomarker, on the strength of the early results.
Hunter Immunology agrees to Probiomics merger
16 December, 2011 by Dylan Bushell-EmblingThe board and largest shareholders of Hunter Immunology have agreed to endorse a reverse takeover by Probiomics (ASX:PCC) to create a company with a $37.2m market cap.
BioDiem buys Savine Therapeutics
15 December, 2011 by Dylan Bushell-EmblingVaccine company BioDiem (ASX:BDM) has added antigen development technology to its portfolio with the purchase of Savine Therapeutics.
IQnovate completes public listing on NSX
15 December, 2011 by Dylan Bushell-EmblingShares in contract medical services company IQnovate (NSX:IQN) start strong, but then pare some of their early gains, during the first day of public trading.
Compumedics wins $1m EEG deal
15 December, 2011 by Dylan Bushell-EmblingCompumedics (ASX:CMP) has picked up a deal to supply an EEG system to the Yale School of Medicine.
